Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) progresses from simple steatosis to metabolic dysfunction–associated steatohepatitis (MASH), yet its therapeutic development has been hampered by pathological complexity and heterogeneity. Methods: Bulk RNA-seq and diet-in...
ORGANISM(S): Mus Musculus
